Bovine Respiratory Disease Complex

PARSIPPANY, N.J.--( BUSINESS WIRE )-- Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023. The company reported revenue of $2.0 billion for the fourth quarter of 2022, which was an increase of 4% compared with the fourth quarter of 2021. On an operational 1 basis, revenue for the fourth quarter of 2022 increased 9% compared with the fourth quarter of 2021, excluding the impact of foreign currency. Net income for the fourth quarter of 2022 was $461 million, or $0.99 per diluted share, an increase of 11% and 14%, respectively, on a reported basis. Adjusted net income for the fourth quarter of 2022 was $539 million, or $1.15 per diluted share, an increase of 14% and 15%, respectively, on a reported basis. Adjusted net income for the fourth quarter of 2022 excludes the net impact of $78 million for purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted net income 2 for the fourth quarter of 2022 increased 27% operationally, excluding the impact from foreign currency. For full year 2022, the company reported revenue of $8.1 billion, an increase of 4% compared with full year 2021. On an operational basis, revenue for full year 2022 increased 8%, excluding the impact of foreign currency. Net income for full year 2022 was $2.1 billion, or $4.49 per diluted share, an increase of 4% and 5%, respectively, on a reported basis. Adjusted net income for full year 2022 was $2.3 billion, or $4.88 per diluted share, an increase of 3% and 4%, respectively, on a reported basis. Adjusted net income for full year 2022 excludes the net impact of $183 million for purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted net income for full year 2022 increased 11% operationally, excluding the impact of foreign currency. EXECUTIVE COMMENTARY “In 2022, Zoetis delivered another strong year of performance thanks to our diverse portfolio, global scale and talented colleagues,” said Kristin Peck, Chief Executive Officer of Zoetis. “We grew revenue 8% operationally, driven by our innovative companion animal franchises across parasiticides, dermatology and pain. We also grew our adjusted net income faster than sales for the year, at 11% operationally, while continuing to support investments in R&D, manufacturing capacity, and sales and marketing efforts that will drive future growth." "Looking ahead, we are well-positioned with the strategy and capabilities to expand in large and growing product areas like parasiticides, dermatology products, monoclonal antibodies, vaccines and diagnostics, while still investing in comprehensive solutions across the continuum of animal care. We are committed to continuing our track record of value creation and above-market performance even in the face of today’s economic uncertainty, and we are guiding to full-year operational growth of 6% to 8% in revenue in 2023," said Peck. QUARTERLY HIGHLIGHTS Zoetis organizes and manages its commercial operations across two regional segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock tailored to local trends and customer needs. In the fourth quarter of 2022: Revenue in the U.S. segment was $1.112 billion, an increase of 7% compared with the fourth quarter of 2021. Sales of companion animal products increased 12%, driven by growth in the company’s parasiticide portfolio, primarily Simparica Trio ® for dogs. The company’s key dermatology portfolio also contributed to growth across both the Apoquel ® and Cytopoint ® brands. Sales of livestock products declined 6% in the quarter. Sales of cattle products declined as a result of supply re-stocking in the third quarter of 2022 and generic competition for Draxxin ® . The company’s poultry portfolio declined due to the expanded use of lower cost alternatives and generic competition for Zoamix ® , the company’s alternative to antibiotics in medicated feed additives. Sales of swine products also decreased modestly in the quarter. Revenue in the International segment was $901 million, essentially flat on a reported basis and an increase of 12% operationally compared with the fourth quarter of 2021. Sales of companion animal products grew 7% on a reported basis and 21% operationally. Contributing to growth in the quarter was the company’s parasiticide portfolio, primarily Revolution ® and Simparica ® , as well as key dermatology products including the recently launched chewable version of Apoquel. Also contributing to growth in the quarter were the company’s monoclonal antibody products for osteoarthritis pain, Librela ® for dogs and Solensia ® for cats. Sales of livestock products declined 7% on a reported basis and increased 4% operationally. Growth in the company’s fish portfolio was the result of increased sales of vaccines across key salmon markets, including Norway and Chile. Sales of the company’s poultry portfolio grew due to market expansion and demand generation efforts in several key geographies, while sales of sheep products grew due to the acquisition of Jurox in Australia. Growth in fish, poultry and sheep was partially offset by reduced sales in the company’s swine and cattle portfolios due primarily to supply constraints. INVESTMENTS IN GROWTH Zoetis continues to grow key product franchises through new product approvals and incremental claim extensions. On the companion animal side of the business, Simparica Trio (sarolaner/moxidectin/pyrantel) received approval in the European Union (EU) and the U.K. for additional claims related to faster kill time of ticks. In livestock, Fostera ® Gold PCV MH , a one-shot vaccine for pigs that offers the longest lasting combined protection against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae infections, was approved for use in pregnant gilts and sows in the U.S., EU and Canada, expanding its original claims. In Canada, the company’s fifth largest market by revenue in 2022, Zoetis gained approvals for two key livestock products: Protivity ® , the first modified live vaccine to offer protection against Mycoplasma bovis, providing cattle producers and veterinarians with broader overall protection against bovine respiratory disease (BRD), as well as Poulvac ® Procerta ® HVT-IBD-ND , a part of the company’s recombinant vector vaccine portfolio for poultry, which provides early, robust protection against Marek’s, infectious bursal and Newcastle disease viruses with one dose. In Diagnostics, Zoetis expanded its multi-purpose Vetscan Imagyst™ platform in the U.S. to include new applications for artificial intelligence (AI) dermatology and AI equine Fecal Egg Count (FEC) analysis. These additions broaden the platform’s testing capabilities for veterinarians, redefining what is possible for veterinary diagnosis and animal care across species. FINANCIAL GUIDANCE Zoetis is providing full year 2023 guidance, which includes: Revenue between $8.575 billion to $8.725 billion ( operational growth of 6% to 8%) Reported net income between $2.345 billion to $2.400 billion Adjusted net income between $2.490 billion to $2.540 billion ( operational growth of 7% to 9%) Reported diluted EPS between $5.03 to $5.14 Adjusted diluted EPS between $5.34 to $5.44 This guidance reflects foreign exchange rates as of late January. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning. WEBCAST & CONFERENCE CALL DETAILS Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2022 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . A replay of the webcast will be archived and made available on February 14, 2023. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com . 1 Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. 2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items. DISCLOSURE NOTICES Forward-Looking Statements : This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; disruptions in our global supply chain; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rate and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , www.zoetis.com , or on request from Zoetis. Use of Non-GAAP Financial Measures : We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com . Internet Posting of Information : We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com , on our Facebook page at http://www.facebook.com/zoetis and on Twitter@zoetis . We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us. ZTS-COR ZTS-IR ZTS-FIN ZOETIS INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (a) (UNAUDITED) (millions of dollars, except per share data) Three Months Ended December 31, % Change Twelve Months Ended December 31, % Change 2022 2021 2022 2021 Revenue $ 2,040 $ 1,967 4 $ 8,080 $ 7,776 4 Costs and expenses: Cost of sales 653 600 9 2,454 2,303 7 Selling, general and administrative expenses 514 593 (13) 2,009 2,001 — Research and development expenses 148 138 7 539 508 6 Amortization of intangible assets 35 40 (13) 150 161 (7) Restructuring charges and certain acquisition-related costs 2 4 (50) 11 43 (74) Interest expense 62 54 15 221 224 (1) Other (income)/deductions–net 34 32 6 40 48 (17) Income before provision for taxes on income 592 506 17 2,656 2,488 7 Provision for taxes on income 132 93 42 545 454 20 Net income before allocation to noncontrolling interests 460 413 11 2,111 2,034 4 Less: Net loss attributable to noncontrolling interests (1) (1) — (3) (3) — Net income attributable to Zoetis $ 461 $ 414 11 $ 2,114 $ 2,037 4 Earnings per share—basic $ 0.99 $ 0.88 13 $ 4.51 $ 4.29 5 Earnings per share—diluted $ 0.99 $ 0.87 14 $ 4.49 $ 4.27 5 Weighted-average shares used to calculate earnings per share Basic 465.6 473.1 468.9 474.3 Diluted 466.8 475.6 470.4 476.7 (a) The Condensed Consolidated Statements of Income present the three and twelve months ended December 31, 2022 and 2021. Subsidiaries operating outside the U.S. are included for the three and twelve months ended November 30, 2022 and 2021. ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) Three Months Ended December 31, 2022 GAAP Reported (a) Purchase Accounting Adjustments Acquisition- Related Costs (1) Certain Significant Items (2) Non-GAAP Adjusted (b) Cost of sales $ 653 $ (3 ) $ — $ — $ 650 Gross profit 1,387 3 — — 1,390 Selling, general and administrative expenses 514 (7 ) — — 507 Research and development expenses 148 (1 ) — — 147 Amortization of intangible assets 35 (29 ) — — 6 Restructuring charges and certain acquisition-related costs 2 — (1 ) (1 ) — Other (income)/deductions–net 34 — — (45 ) (11 ) Income before provision for taxes on income 592 40 1 46 679 Provision for taxes on income 132 12 — (3 ) 141 Net income attributable to Zoetis 461 28 1 49 539 Earnings per common share attributable to Zoetis–diluted 0.99 0.06 — 0.10 1.15 Three Months Ended December 31, 2021 GAAP Reported (a) Purchase Accounting Adjustments Acquisition- Related Costs (1) Certain Significant Items (2) Non-GAAP Adjusted (b) Cost of sales $ 600 $ (1 ) $ — $ (1 ) $ 598 Gross profit 1,367 1 — 1 1,369 Selling, general and administrative expenses 593 (7 ) — — 586 Amortization of intangible assets 40 (34 ) — — 6 Restructuring charges and certain acquisition-related costs 4 — (4 ) — — Other (income)/deductions–net 32 — — (28 ) 4 Income before provision for taxes on income 506 42 4 29 581 Provision for taxes on income 93 9 1 5 108 Net income attributable to Zoetis 414 33 3 24 474 Earnings per common share attributable to Zoetis–diluted 0.87 0.07 0.01 0.05 1.00 (a) The Condensed Consolidated Statements of Income present the three months ended December 31, 2022 and 2021. Subsidiaries operating outside the U.S. are included for the three months ended November 30, 2022 and 2021. (b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) Twelve Months Ended December 31, 2022 GAAP Reported (a) Purchase Accounting Adjustments Acquisition- Related Costs (1) Certain Significant Items (2) Non-GAAP Adjusted (b) Cost of sales $ 2,454 $ (6 ) $ — $ (8 ) $ 2,440 Gross profit 5,626 6 — 8 5,640 Selling, general and administrative expenses 2,009 (29 ) — — 1,980 Research and development expenses 539 (1 ) — — 538 Amortization of intangible assets 150 (124 ) — — 26 Restructuring charges and certain acquisition-related costs 11 — (5 ) (6 ) — Other (income)/deductions–net 40 — — (42 ) (2 ) Income before provision for taxes on income 2,656 160 5 56 2,877 Provision for taxes on income 545 40 1 (3 ) 583 Net income attributable to Zoetis 2,114 120 4 59 2,297 Earnings per common share attributable to Zoetis–diluted 4.49 0.26 0.01 0.12 4.88 Twelve Months Ended December 31, 2021 GAAP Reported (a) Purchase Accounting Adjustments Acquisition- Related Costs (1) Certain Significant Items (2) Non-GAAP Adjusted (b) Cost of sales $ 2,303 $ (6 ) $ — $ (8 ) $ 2,289 Gross profit 5,473 6 — 8 5,487 Selling, general and administrative expenses 2,001 (30 ) — — 1,971 Research and development expenses 508 (1 ) — — 507 Amortization of intangible assets 161 (138 ) — — 23 Restructuring charges and certain acquisition-related costs 43 — (12 ) (31 ) — Other (income)/deductions–net 48 — — (34 ) 14 Income before provision for taxes on income 2,488 175 12 73 2,748 Provision for taxes on income 454 39 2 16 511 Net income attributable to Zoetis 2,037 136 10 57 2,240 Earnings per common share attributable to Zoetis–diluted 4.27 0.29 0.02 0.12 4.70 (a) The Condensed Consolidated Statements of Income present the twelve months ended December 31, 2022 and 2021. Subsidiaries operating outside the U.S. are included for the twelve months ended November 30, 2022 and 2021. (b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). ZOETIS INC. NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars) (1) Acquisition-related costs include the following: Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Transaction costs (a) $ 1 $ — $ 1 $ — Integration costs (b) — 4 4 10 Restructuring charges (c) — — — 2 Total acquisition-related costs—pre-tax 1 4 5 12 Income taxes (d) — 1 1 2 Total acquisition-related costs—net of tax $ 1 $ 3 $ 4 $ 10 (a) Represents external costs directly related to acquiring businesses and primarily includes expenditures for banking, legal, accounting and other similar services. Included in Restructuring charges and certain acquisition-related costs . (b) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs . (c) Represents exit and employee termination costs, included in Restructuring charges and certain acquisition-related costs. (d) Included in Provision for taxes on income . Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. (2) C ertain significant items include the following: Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Other restructuring charges and cost-reduction/productivity initiatives (a) $ 1 $ 2 $ 8 $ 24 Certain asset impairment charges (b) 41 27 47 46 Net loss on sale of assets (c) — — — 3 Other 4 — 1 — Total certain significant items—pre-tax 46 29 56 73 Income taxes (d) (3 ) 5 (3 ) 16 Total certain significant items—net of tax $ 49 $ 24 $ 59 $ 57 (a) For the twelve months ended December 31, 2022, primarily represents employee termination and exit costs associated with cost-reduction and productivity initiatives in certain international markets, included in Restructuring charges and certain acquisition-related costs , as well as product transfer costs, included in Cost of sales. For the twelve months ended December 31, 2021, primarily represents employee termination costs associated with the realignment of our international operations and other costs associated with cost-reduction and productivity initiatives, included in Restructuring charges and certain acquisition-related costs . (b) For the three and twelve months ended December 31, 2022, primarily represents asset impairment charges related to customer relationships, developed technology rights and property, plant and equipment in our diagnostics, poultry, cattle and swine businesses included in Other (income)/deductions-net. For the twelve months ended December 31, 2022, also includes inventory and certain asset impairment charges related to the consolidation of manufacturing sites in China, included in Cost of sales and Restructuring charges and certain acquisition related costs. For the three months ended December 31, 2021, represents asset impairment charges related to developed technology rights and trademarks in our dairy cattle, diagnostics and aquatic health businesses, included in Other (income)/deductions-net . For the twelve months ended December 31, 2021, primarily represents asset impairment charges related to: Developed technology rights and trademarks in our dairy cattle, diagnostics and aquatic health businesses, included in Other (income)/deductions-net; The consolidation of manufacturing sites in China, included in Restructuring charges and certain acquisition related costs; and Property, plant and equipment and inventory related to a dairy product termination included in Other (income)/deductions-net and Cost of sales . (c) Represents a net loss related to the sale of certain assets of our poultry automation business located in the U.S. and Canada, included in Other (income)/deductions-net . (d) Included in Provision for taxes on income . Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. For the twelve months ended December 31, 2022, also includes a tax charge related to changes in valuation allowances related to impairment of certain assets and changes in uncertain tax positions. ZOETIS INC. ADJUSTED SELECTED COSTS AND EXPENSES (a) (UNAUDITED) (millions of dollars) Three Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) Adjusted cost of sales $ 650 $ 598 9 % (2 ) % 11 % As a percent of revenue 31.9 % 30.4 % NA NA NA Adjusted SG&A expenses 507 586 (13 ) % (4 ) % (9 ) % Adjusted R&D expenses 147 138 7 % (3 ) % 10 % Adjusted net income attributable to Zoetis 539 474 14 % (13 ) % 27 % Twelve Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) Adjusted cost of sales $ 2,440 $ 2,289 7 % (1 ) % 8 % As a percent of revenue 30.2 % 29.4 % NA NA NA Adjusted SG&A expenses 1,980 1,971 — % (3 ) % 3 % Adjusted R&D expenses 538 507 6 % (2 ) % 8 % Adjusted net income attributable to Zoetis 2,297 2,240 3 % (8 ) % 11 % (a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs, and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. ZOETIS INC. 2023 GUIDANCE Selected Line Items (millions of dollars, except per share amounts) Full Year 2023 Revenue $8,575 to $8,725 Operational growth (a) 6% to 8% Adjusted cost of sales as a percentage of revenue (b) 29.5% to 30.0% Adjusted SG&A expenses (b) $2,060 to $2,100 Adjusted R&D expenses (b) $635 to $660 Adjusted interest expense and other (income)/deductions-net (b) Approximately $170 Effective tax rate on adjusted income (b) 20.0% to 21.0% Adjusted diluted EPS (b) $5.34 to $5.44 Adjusted net income (b) $2,490 to $2,540 Operational growth (a)(c) 7% to 9% Certain significant items and acquisition-related costs (d) $20 - $25 The guidance reflects foreign exchange rates as of late January. Reconciliations of 2023 reported guidance to 2023 adjusted guidance follows: (millions of dollars, except per share amounts) Reported Certain significant items and acquisition-related costs (d) Purchase accounting Adjusted (b) Cost of sales as a percentage of revenue 29.7% to 30.2% ~ (0.1%) ~ (0.1%) 29.5% to 30.0% SG&A expenses $2,090 to $2,130 ~ $(30) $2,060 to $2,100 R&D expenses $636 to $661 ~ $(1) $635 to $660 Interest expense and other (income)/deductions ~ $170 ~ $170 Effective tax rate 20.0% to 21.0% 20.0% to 21.0% Diluted EPS $5.03 to $5.14 $0.04 - $0.05 ~ $0.26 $5.34 to $5.44 Net income attributable to Zoetis $2,345 to $2,400 $20 - $25 ~ $120 $2,490 to $2,540 (a) Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange. (b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. (c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. (d) Primarily includes certain nonrecurring costs related to acquisitions and other charges. ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT (a) AND SPECIES (UNAUDITED) (millions of dollars) Three Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) Revenue: Companion Animal $ 1,303 $ 1,182 10 % (5 ) % 15 % Livestock 710 760 (7 ) % (7 ) % — % Contract Manufacturing & Human Health 27 25 8 % (4 ) % 12 % Total Revenue $ 2,040 $ 1,967 4 % (5 ) % 9 % U.S. Companion Animal $ 853 $ 763 12 % — % 12 % Livestock 259 277 (6 ) % — % (6 ) % Total U.S. Revenue $ 1,112 $ 1,040 7 % — % 7 % International Companion Animal $ 450 $ 419 7 % (14 ) % 21 % Livestock 451 483 (7 ) % (11 ) % 4 % Total International Revenue $ 901 $ 902 — % (12 ) % 12 % Companion Animal: Dogs and Cats $ 1,224 $ 1,107 11 % (4 ) % 15 % Horses 79 75 5 % (6 ) % 11 % Total Companion Animal Revenue $ 1,303 $ 1,182 10 % (5 ) % 15 % Livestock: Cattle $ 377 $ 413 (9 ) % (5 ) % (4 ) % Swine 138 155 (11 ) % (8 ) % (3 ) % Poultry 115 118 (3 ) % (6 ) % 3 % Fish 61 55 11 % (14 ) % 25 % Sheep and other 19 19 — % (14 ) % 14 % Total Livestock Revenue $ 710 $ 760 (7 ) % (7 ) % — % (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. (b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT (a) AND SPECIES (UNAUDITED) (millions of dollars) Twelve Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) Revenue: Companion Animal $ 5,203 $ 4,689 11 % (3 ) % 14 % Livestock 2,791 3,005 (7 ) % (5 ) % (2 ) % Contract Manufacturing & Human Health 86 82 5 % (2 ) % 7 % Total Revenue $ 8,080 $ 7,776 4 % (4 ) % 8 % U.S. Companion Animal $ 3,341 $ 2,990 12 % — % 12 % Livestock 972 1,052 (8 ) % — % (8 ) % Total U.S. Revenue $ 4,313 $ 4,042 7 % — % 7 % International Companion Animal $ 1,862 $ 1,699 10 % (9 ) % 19 % Livestock 1,819 1,953 (7 ) % (7 ) % — % Total International Revenue $ 3,681 $ 3,652 1 % (8 ) % 9 % Companion Animal: Dogs and Cats $ 4,939 $ 4,426 12 % (3 ) % 15 % Horses 264 263 — % (4 ) % 4 % Total Companion Animal Revenue $ 5,203 $ 4,689 11 % (3 ) % 14 % Livestock: Cattle $ 1,440 $ 1,557 (8 ) % (5 ) % (3 ) % Swine 565 659 (14 ) % (4 ) % (10 ) % Poultry 476 507 (6 ) % (4 ) % (2 ) % Fish 212 187 13 % (9 ) % 22 % Sheep and other 98 95 3 % (9 ) % 12 % Total Livestock Revenue $ 2,791 $ 3,005 (7 ) % (5 ) % (2 ) % (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. (b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. ZOETIS INC. CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS (UNAUDITED) (millions of dollars) Three Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (a) Total International $ 901.3 $ 902.3 — % (12 ) % 12 % Australia 64.2 62.8 2 % (13 ) % 15 % Brazil 96.2 84.1 14 % 4 % 10 % Canada 65.2 63.0 3 % (8 ) % 11 % Chile 34.8 36.1 (4 ) % (5 ) % 1 % China 91.4 68.4 34 % (14 ) % 48 % France 35.1 34.7 1 % (16 ) % 17 % Germany 44.0 48.0 (8 ) % (14 ) % 6 % Italy 25.6 27.9 (8 ) % (14 ) % 6 % Japan 36.1 46.3 (22 ) % (21 ) % (1 ) % Mexico 35.6 34.8 2 % 3 % (1 ) % Spain 21.3 31.1 (32 ) % (12 ) % (20 ) % United Kingdom 60.3 61.2 (1 ) % (18 ) % 17 % Other Developed 114.6 117.1 (2 ) % (16 ) % 14 % Other Emerging 176.9 186.8 (5 ) % (14 ) % 9 % Twelve Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (a) Total International $ 3,680.8 $ 3,651.9 1 % (8 ) % 9 % Australia 288.7 258.8 12 % (9 ) % 21 % Brazil 329.5 311.5 6 % 3 % 3 % Canada 237.5 231.5 3 % (3 ) % 6 % Chile 141.1 136.3 4 % (4 ) % 8 % China 382.4 357.3 7 % (4 ) % 11 % France 126.1 132.4 (5 ) % (12 ) % 7 % Germany 176.3 183.0 (4 ) % (12 ) % 8 % Italy 111.2 115.2 (3 ) % (11 ) % 8 % Japan 173.1 186.2 (7 ) % (16 ) % 9 % Mexico 136.2 132.6 3 % — % 3 % Spain 117.8 127.7 (8 ) % (11 ) % 3 % United Kingdom 234.5 234.4 — % (11 ) % 11 % Other Developed 468.4 467.0 — % (11 ) % 11 % Other Emerging 758.0 778.0 (3 ) % (12 ) % 9 % (a) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. ZOETIS INC. SEGMENT (a) EARNINGS (UNAUDITED) (millions of dollars) Three Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) U.S.: Revenue $ 1,112 $ 1,040 7 % — % 7 % Cost of sales 216 213 1 % — % 1 % Gross profit 896 827 8 % — % 8 % Gross margin 80.6 % 79.5 % Operating expenses 187 197 (5 ) % — % (5 ) % Other (income)/deductions-net (12 ) 2 * * * U.S. Earnings $ 721 $ 628 15 % — % 15 % International: Revenue $ 901 $ 902 — % (12 ) % 12 % Cost of sales 274 273 — % (8 ) % 8 % Gross profit 627 629 — % (13 ) % 13 % Gross margin 69.6 % 69.7 % Operating expenses 155 173 (10 ) % (10 ) % — % Other (income)/deductions-net 2 — * * * International Earnings $ 470 $ 456 3 % (14 ) % 17 % Total Reportable Segments $ 1,191 $ 1,084 10 % (6 ) % 16 % Other business activities (c) (109 ) (105 ) 4 % Reconciling Items: Corporate (d) (302 ) (308 ) (2 ) % Purchase accounting adjustments (e) (40 ) (42 ) (5 ) % Acquisition-related costs (f) (1 ) (4 ) (75 ) % Certain significant items (g) (46 ) (29 ) 59 % Other unallocated (h) (101 ) (90 ) 12 % Total Earnings (i) $ 592 $ 506 17 % (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. (c) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health business. (d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest expense, certain compensation costs, certain procurement costs, and other costs not charged to our operating segments. (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. (f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with a shift in our organizational structure and cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, costs associated with the operational efficiency initiative and supply network strategy, and the impact of divestiture-related gains and losses. (h) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. (i) Defined as income before provision for taxes on income. * Calculation not meaningful. ZOETIS INC. SEGMENT (a) EARNINGS (UNAUDITED) (millions of dollars) Twelve Months Ended December 31, % Change 2022 2021 Total Foreign Exchange Operational (b) U.S.: Revenue $ 4,313 $ 4,042 7 % — % 7 % Cost of sales 803 788 2 % — % 2 % Gross profit 3,510 3,254 8 % — % 8 % Gross margin 81.4 % 80.5 % Operating expenses 765 681 12 % — % 12 % Other (income)/deductions-net (18 ) 4 * * * U.S. Earnings $ 2,763 $ 2,569 8 % — % 8 % International: Revenue $ 3,681 $ 3,652 1 % (8 ) % 9 % Cost of sales 1,083 1,106 (2 ) % (5 ) % 3 % Gross profit 2,598 2,546 2 % (10 ) % 12 % Gross margin 70.6 % 69.7 % Operating expenses 611 602 1 % (8 ) % 9 % Other (income)/deductions-net (3 ) (4 ) (25 ) % 28 % (53 ) % International Earnings $ 1,990 $ 1,948 2 % (10 ) % 12 % Total Reportable Segments $ 4,753 $ 4,517 5 % (5 ) % 10 % Other business activities (c) (424 ) (406 ) 4 % Reconciling Items: Corporate (d) (1,073 ) (1,052 ) 2 % Purchase accounting adjustments (e) (160 ) (175 ) (9 ) % Acquisition-related costs (f) (5 ) (12 ) (58 ) % Certain significant items (g) (56 ) (73 ) (23 ) % Other unallocated (h) (379 ) (311 ) 22 % Total Earnings (i) $ 2,656 $ 2,488 7 % (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. (b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange. (c) Other business activities reflect the research and development costs managed by our Research and Development organization as well as our contract manufacturing business and human health business. (d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest expense, certain (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. (f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs. (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with a shift in our organizational structure and cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated with the operational efficiency initiative and supply network strategy, and the impact of divestiture-related gains and losses. (h) Includes overhead expenses associated with our manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. (i) Defined as income before provision for taxes on income. * Calculation not meaningful.

Nerve sensitization is a serious and underdiagnosed stress-related condition. SCOTTSDALE, Ariz., Jan. 25, 2023 /PRNewswire/ -- Severe headaches, digestive issues, and chronic neck and back pain can result when stress isn't properly identified and managed. Known as central sensitization syndromes (CSS), the debilitating conditions are often missed by traditional healthcare practices, leading to a long-lasting disability. Under high stress, the body's weakest link breaks, which may mean headaches, back pain, or digestive issues. With sensitization, the nerves are more sensitive to stimuli. The nerves and the brain relay the message of extreme pain. The physical impact of touch, pressure, and movement are heightened in a person with nerve sensitization. In addition to the pain, symptoms can include fatigue, brain fog, disrupted sleep, and sensitivity to light, sound, and smells. According to Dr. Johnson, CSS sufferers struggle to get through their work day, their energy levels half of before. Difficulties concentrating make the work they do get through harder. Dr. Shana Johnson, a board-certified physical medicine and rehabilitation physician, specializes in treating these disorders. Her interest arose from her own bout with a stress-related disorder. "I can personally relate to my patients' pain and emotional distress," explains Dr. Johnson. "I had very real symptoms of agonizing pain. Conventional tests weren't able to show what was wrong. Initially, providers dismissed my symptoms. I had to put the pieces together for myself." She adds that when nerve sensitization is missed, people often seek out opioids, because they are confused and desperate for relief. A physician heals herself When her symptoms began, Dr. Johnson was working in neurology, treating people with conditions that impact the brain, spine, and nerves. She managed a clinic for multiple sclerosis and also treated traumatic brain injuries, spinal cord injuries, and stroke survivors. Her work and her personal physical pain prompted Dr. Johnson to further explore the science behind what she knew was a true medical condition. "With CSS, the patient feels pain more easily, more intensely, and in more places. For example, you might lift a 50-pound box and feel a pull in your back. A CSS sufferer lifts a 25-pound box and the pain is excruciating." explains Dr. Johnson, author of the forthcoming book on the subject, Sunbreak. "There are many ways to manage the symptoms of CSS," Dr. Shana Johnson concludes. "But it starts with seeking help from a provider who understands the condition." For more information, visit SOURCE Ask Dr Shana

Policy-minded health care providers band together to support patients with rare, chronic condition called IgG4-RD WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- A new initiative from the nonprofit Alliance for Patient Access brings together clinicians from across the country to identify unmet needs and to improve treatment access for patients living with IgG4-RD. The rare and chronic autoimmune disease is sometimes associated with type 1 autoimmune pancreatitis. The group will work to provide solutions to access challenges and to raise awareness, in addition to encouraging treatment research and innovation. "Facing a disease that few people have ever even heard of can be isolating and scary," said Josie Cooper, executive director of the Alliance for Patient Access. "The clinician members of the IgG4-RD Initiative are committed to supporting patients through education and advocacy." The Alliance for Patient Access released a "Fast Facts," an educational Q&A document, to coincide with the IgG4-RD initiative launch. The paper provides introductory information on the disease for patients as well as for providers for whom the disease may be unfamiliar. ABOUT IgG4-RD IgG4-RD is a rare and chronic autoimmune disease. Symptoms vary and may include: brain fog, double vision, fatigue, severe body or eye pain, and sinus pressure. Patients are often treated by a rheumatologist. Because IgG4-RD was discovered only recently, there isn't yet an FDA-approved treatment for the condition, though options may be on the horizon. LEARN MORE Fast Facts: Understanding IgG4-RD Report: In their Own Voices – The Lived Experiences of IgG4-RD Patients Report: In their Own Voices, 2022 Update About the Alliance for Patient Access The Alliance for Patient Access is a national network of policy-minded health care providers who advocate for patient-centered care. About the Alliance for Patient Access Rare Diseases Working Group The Rare Diseases Working Group is comprised of policy-minded health care professionals focused on ensuring that rare disease patients have appropriate access to patient-centered care. SOURCE Alliance for Patient Access